Notwithstanding these open questions, the tumor cell death elicited by KAT2A/SRSF11 inhibition—selectively disabling HR without perturbing NHEJ—positions this pathway as a precision therapeutic vulnerability in radiation oncology. The gene discussed is KAT2A; the disease is neoplasm.